In The News

This page contains articles written by persons not affiliated with vTv Therapeutics. The views expressed in the articles are those of the author and do not reflect the views of the company. vTv Therapeutics disavows any obligation to update or correct the information contained in these articles.

Hypoglycemia in Type 1 Diabetes: Near term challenges, long-term risks, and the need for new therapeutics options

Carmen Valcarce, Executive Vice President and Chief Scientific Officer of vTv Therapeutics discusses the complex issues surrounding the treatment of type 1 diabetes, looking in particular at hypoglycemia and the impact it has both on patients and researchers.
Read More

This article is taken from Pharmafile Spring 2021, pages 39-41 © Samedan Ltd

Realize the Potential of Adjunctive Therapy in the Treatment of Type 1 Diabetes

One approach to improve care and clinical outcomes for people with type 1 diabetes involves the use of adjunctive therapies along with insulin to improve glucose control or enable reductions in insulin doses.
Read More

VTV Celebrates a Double Positive

Yesterday’s clinical study success has underlined VTV’s status as a small-cap bet on Alzheibetes.
Read More

Vtv scores phase II TD in T1D as Alzheimer’s bid RAGEs against dying of light

Read More